Betagan From Allergan With Levobunolol Hydrochloride 0.25%

Ingredients: Levobunolol Hydrochloride
Dosage Form and Administration: Solution/drops; Ophthalmic
Drug Trade Name: Betagan
Firm: Allergan
Strength: 0.25%
New Drug Application Type: N
Drug Application Number:19814
Product Number: 1
Approval Date: 6/28/1989
Reference Listed Drug: Yes
Type: RX
Applicant Full Name: Allergan Pharmaceutical

Childhood Weight-Control Program

Think about a treatment program if: A change in eating and physical activity habits has not impacted the health of the child or if a health care provider advised that the health or emotional well being of the child is at risk because of his or her weight.
The overall goal of a treatment program should be to help the whole family adopt healthy eating and physical activity habits that will last a lifetime. A weight-control program should also: include a variety of health care professionals on staff, including doctors, registered dietitians, psychiatrists or psychologists and exercise physiologists. Staff should evaluate the weight, growth and health of the child before enrolling him or her in the program. The program should also monitor these factors while the child participates in the program. The program should adapt to the specific age and abilities of the child. Programs for 4-year-olds should be different from those for 12-year-olds.

Co-Occurring Drug Abuse and Mental Health

Offenders with co-occurring drug abuse and mental health problems often require an integrated treatment approach. High rates of mental health problems are present in offender populations and in those with substance abuse problems. Drug abuse treatment can sometimes address depression, anxiety and other mental health problems. Personality, cognitive and other serious mental disorders can be difficult to treat and may disrupt drug treatment. The presence of co-occurring disorders may require an integrated approach that combines drug abuse treatment with psychiatric treatment, including the use of medication. A physician should assess Individuals with either a substance abuse or mental health problem for the presence of the other.

Medications for Drug Abuse

Medications are important parts of treatment for many drug abusing offenders. For heroin addiction, medicines such as methadone and buprenorphine help normalize brain function and individuals who may benefit from them should take them. Effective use of medications can be instrumental in enabling people with co-occurring mental health problems to function successfully in society. Behavioral strategies can increase adherence to medication regimens.

Chronic Conditions Prevention

Treatment planning for drug abusing offenders who are living in or returning the community should include strategies to prevent and treat serious, chronic medical conditions, such as HIV/AIDS, hepatitis B and C and tuberculosis.
The rates of infectious diseases, such as hepatitis, tuberculosis and HIV/AIDS, are higher in drug abusers, incarcerated offenders and offenders under community supervision than in the general population. Infectious diseases affect not just the offender, but also the criminal justice system and the wider community. Consistent with federal and state laws, offenders who have abused drugs should be tested for infectious diseases and receive counseling on health practices and on ways to modify risky behaviors. Probation and parole officers who monitor offenders with serious medical conditions should link them with appropriate healthcare services, encourage compliance with medical treatment and re-establish eligibility of the offender for public health services like Medicaid.